Mundipharma presents wealth of data for Penthrox®▼ (methoxyflurane) at EUSEM Congress, demonstrating superiority compared to standard of care in trauma pain in adults
FOR EUROPEAN MEDICAL AND TRADE MEDIA ONLY
Mundipharma presents new data for the inhaled analgesic Penthrox ® (methoxyflurane)6 at the European Society for Emergency Medicine (EUSEM) Congress 2019, from 12–16 October. Five abstracts are being presented, advancing the understanding of the use of methoxyflurane in the treatment of moderate to severe trauma-related pain for adults in emergency settings in Europe:
MEDITA Study1 #18647: the first study to directly compare the effectiveness of methoxyflurane to standard analgesic treatment (SAT) – IV morphine for severe pain, and IV paracetamol or ketoprofen for moderate trauma pain in Italy.
- Methoxyflurane was superior to IV morphine (severe pain) and IV paracetamol or IV ketoprofen (moderate pain) for the primary endpoint, defined as the change in pain intensity over the first 10 minutes (overall adjusted mean treatment difference: 5.94mm; 95% CI: 8.83, 3.06mm) following pain treatment administration.1
- Methoxyflurane was rated as ‘excellent’, ‘very good’ or ‘good’ by significantly more patients in the methoxyflurane group, compared to the SAT group (72.7% vs 60.9%; p=0.001) and significantly more healthcare professionals rated the practicality of methoxyflurane as ‘excellent’, ‘very good’ or ‘good’, compared to SAT (90.3% vs 64.4%; p<0.001).1
PenASAP Study5 #19302: a placebo-controlled study comparing the effectiveness of methoxyflurane plus standard of care (SoC) analgesia vs SoC analgesia plus placebo for the management of moderate to severe trauma pain in France.
- Results demonstrate the superiority of methoxyflurane in combination with SoC vs placebo plus SoC, in achieving pain relief for patients with moderate to severe trauma pain. For the primary endpoint, the median time to pain relief, defined as 30mm or less on the visual analogue scale, was 35 minutes in the methoxyflurane plus SoC group (p<0.001) and was not reached in the SoC plus placebo group.5
InMEDIATE Study2-4 #18659, #18660, #18661: sub-analyses from a study comparing methoxyflurane to existing SAT in acute moderate to severe trauma pain in Spain.
- Methoxyflurane use in the elderly (at least 65 years old) provided significantly faster pain relief than SAT (time to first pain relief of 5.55 vs 12.8 minutes, and time to first meaningful pain relief of 12.57 vs 25.07 minutes), respectively.2
- In patients with severe trauma-related pain (numerical rating scale score of 7 or more), decrease from baseline was significantly larger for methoxyflurane than SAT at all time points (3, 5, 10, 15 and 20 minutes) (p<0.001), with the largest treatment difference reported at 10 minutes.3
- In patients with acute trauma pain (numerical rating scale score of 4 or more) who received first-step IV analgesic, the decrease from baseline was significantly larger for methoxyflurane than SAT at all time points (3, 5, 10, 15 and 20 minutes) (p<0.001), with the largest treatment difference reported at 10 minutes.4
Methoxyflurane was generally well tolerated in all the studies, with most adverse events (AEs), primarily dizziness, being mild and transient but occurring more frequently than in the comparator groups.2-6 In the PenASAP study, two severe AEs occurred in the methoxyflurane plus SoC group, including one that was assessed as treatment-related.5
“We are very excited by these data demonstrating the superiority of methoxyflurane when compared directly with standard treatment, or compared with placebo when used in addition to SoC for moderate-to-severe trauma pain, in real-world settings in European countries” said Sara Dickerson, Medical Affairs Lead for Mundipharma. “We know that trauma pain is too often undertreated, or even untreated, which can be very distressing for patients and can lead to long-term effects. Results from these studies support the use of methoxyflurane as a simple, fast and effective non-opioid treatment option for adult patients experiencing trauma pain.”
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get to your local medicines regulatory authority.
Notes to editors
About Penthrox® (methoxyflurane)
Penthrox is a small, light-weight, hand-held, inhaled non-opioid analgesic.6,7 It is indicated in Europe for the emergency relief of moderate to severe pain in conscious adults with trauma and associated pain.6,8 It is a self-administered analgesic (under supervision) and provides rapid pain relief within three minutes9 or six to ten inhalations.10,11 Methoxyflurane as an analgesic has been used by more than six million people over the course of 40 years, in Australia and New Zealand.12 It has an established tolerability profile and a body of supporting evidence in adult trauma pain.13,14
Mundipharma International Corporation Limited has exclusive rights to Penthrox in 40 European markets, including France, Germany, Italy and Spain, but excluding the Republic of Ireland and the United Kingdom.
PENTHROX® is a registered trade mark of Medical Developments International Limited and is used under licence.
Click here to watch an animation about the management of trauma pain in Europe: www.mundipharma.com/media_video/taking-the-pain-out-of-trauma/
About Management of Trauma Pain in the Pre-Hospital Setting
33 million people across Europe visit the hospital emergency department due to injuries every year.15 Trauma pain requires fast, effective pain relief (analgesia).7 Although inadequate pain treatment can cause clinical deterioration, pain is undertreated in both the emergency department and pre-hospital setting, and remains a significant problem.7,16 Current analgesics have limitations in pre-hospital settings and there is a need for fast-acting, non-invasive, non-narcotic analgesia.7,17
About the Mundipharma Network
Mundipharma is a global network of privately-owned independent associated companies whose purpose is to move medicine forward. With a high performing and learning organisation that strives for innovation and commercial excellence through partnerships, we successfully transformed and diversified our European portfolio of medicines to create value for patients, payers and wider healthcare systems across important therapeutic areas such as Diabetes, Respiratory, Oncology, Pain and Biosimilars.
1 Serra S, Ruggiano G, Fabbri A, et al. Methoxyflurane versus standard analgesic treatment for acute trauma-related pain in the emergency setting: results of a randomised, controlled study in Italy (MEDITA). Presented at EUSEM 2019. Abstract #18647, Poster P37.
2 Capilla Pueyo R, Fernandez Alonso C, Garcia S, et al. Methoxyflurane, an efficient and well tolerated analgesic for elderly patients, compared with standard analgesic treatment: subgroup analysis of a phase IIIb randomised, controlled trial (InMEDIATE). Presented at EUSEM 2019. Abstract #18659 - OP014.
3 Fernández Alonso C, Garcia Collado S, Carballo Cardona C, et al. Low dose of inhaled Methoxyflurane: more effective and rapid-acting than standard analgesic treatment, also for severe trauma-related pain: subgroup analysis of a randomised controlled trial (InMEDIATE). Presented at EUSEM 2019. Abstract #18660 - SP090.
4 Carballo Cardona C, Capilla Pueyo R, Fernandez Alonso C, et al. Low dose of inhaled methoxyflurane is more effective with higher patient and clinician satisfaction than first-step intravenous analgesic treatment for acute trauma-related pain: subgroup analysis of a phase IIIb randomised controlled trial (InMEDIATE). Presented at EUSEM 2019. Abstract #18661 - OP015.
5 Ricard-Hibon A, Lecoules N, Savary D, et al. A randomised, double blind placebo-controlled study of methoxyflurane plus standard of care analgesia versus placebo plus standard of care analgesia for moderate to severe pain associated with trauma (The PenASAP Study). Presented at EUSEM 2019. Abstract #19302 - OP008.
6 eMC. Penthrox Summary of Product Characteristics. Available at: www.medicines.org.uk/emc/product/1939/smpc/print. Accessed October 2019.
7 Marinangeli F, Reggiardo G, Sblendido A, et al. Prospective, Multicentre Trial of Methoxyflurane for Acute Trauma-Related Pain in Helicopter Emergency Medical Systems and Hostile Environments: METEORA Protocol. Adv Ther 2018;35:2081-92.
8 Medical Developments International. ASX Announcement: Penthrox approved in another 22 European countries 2017. Available at: www.medicaldev.com/news/asx-announcement-penthrox-approved-another-22-european-countries/ Accessed: October 2019.
9 Borobia AM, Garcia Collado S, Carballo Cardona C, et al. Inhaled Methoxyflurane Provides Greater Analgesia and Faster Onset of Action Versus Standard Analgesia in Patients With Trauma Pain: InMEDIATE: A Randomized Controlled Trial in Emergency Departments. Ann Emerg Med 2019; https://doi.org/10.1016/j.annemergmed.2019.07.028
10 Coffey F, Wright J, Hartshorn S, et al. STOP!: a randomised, double-blind, placebo-controlled study of the efficacy and safety of methoxyflurane for the treatment of acute pain. Emerg Med J 2014;31:613-618.
11 Coffey F, Dissmann P, Mirza K, et al. Methoxyflurane Analgesia in Adult Patients in the Emergency Department: A Subgroup Analysis of a Randomized, Double-blind, Placebo-controlled Study (STOP!) Adv Ther 2016;33:2012-2031.
12 Porter KM, Dayan AD, Dickerson S, et al. The role of inhaled methoxyflurane in acute pain management. Open Access Emerg Med 2018;10:149-164.
13 Grindlay J, Babl FE. Efficacy and safety of methoxyflurane analgesia in the emergency department and prehospital setting. Emerg Med Australas 2009;21(1):4-11.
14 Jephcott C, Grummet J, Nguyen N, et al. A review of the safety and efficacy of inhaled methoxyflurane as an analgesic for outpatient procedures. Br J Anaesth 2018;120(5):1040-1048.
15 Eurosafe. Injuries in the European Union: 2013-2015. Available at: www.eurosafe.eu.com/uploads/inline-files/IDB%202013-2015_suppl%20to%206th%20edition%20Injuries%20in%20the%20EU.pdf. Accessed October 2019.
16 Berben SA, Meijs TH, van Dongen RT, et al. Pain prevalence and pain relief in trauma patients in the Accident & Emergency department. Injury 2008;39:578-585.
17 Sinatra R. Causes and Consequences of Inadequate Management of Acute Pain. Pain Med 2010;11:1859-1871.
MBL/PROX-19078a Date of preparation: OCTOBER 2019
Mundipharma International Limited
Tel: +44 (0) 1223 393 009
Tel: +44 (0) 2381 247 327
To arrange an interview with a spokesperson, please contact Makara Health Communications in the first instance, using the contact details above.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress18.9.2020 13:55:00 EEST | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new
Incyte Announces Encouraging Results From Phase 2 Trial of Retifanlimab (INCMGA0012) in Patients With Previously Treated, Advanced Squamous Cell Carcinoma of the Anal Canal18.9.2020 13:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced results from its Phase 2 POD1UM-202 trial evaluating retifanlimab, a PD-1 inhibitor, in previously treated patients with advanced squamous cell carcinoma of the anal canal (SCAC) who have progressed following standard platinum-based chemotherapy. The trial enrolled 94 patients, including those with well-controlled human immunodeficiency virus (HIV) infection (10%). Retifanlimab monotherapy resulted in a confirmed objective response rate (ORR) of 14% as determined by independent central review (ICR) using RECIST v1.1. Responses were observed regardless of PD-L1 status, presence of liver metastases, age or HIV+ status. Retifanlimab was generally well-tolerated with a safety profile as expected of a PD-1 inhibitor and no loss of HIV infection control. Key findings from POD1UM-202: N=94 ORR* (95% CI) 13.8% (7.6-22.5) Best OR*, n 1 CR 12 PR 33 SD DCR 48.9% DOR, median (95% CI), months 9.5 (5.6-NE) PFS, median (95% CI), months 2.3 (1.9-3.6) OS, median (95
Sigfox and Cube Infrastructure Managers Announce Major Partnership in IoT Infrastructure18.9.2020 10:30:00 EEST | Press release
Sigfox, the global 0G network1 and cloud provider for industrial data, is proud to announce a new strategic alliance with Cube Infrastructure Managers (Cube), through the sale of its German 0G network to Cube. Sigfox has grown its 0G IoT services by rolling out 0G networks across 72 countries and regions, which was largely achieved with partners called Sigfox Operators. These operators are the owners of the 0G networks, which they operate as exclusive connectivity providers of Sigfox IoT services, offering worldwide connectivity to customers. The sale of the German network to Cube will allow Sigfox to finance its continued innovation efforts in data value extraction and improvements in cloud algorithms to reduce energy consumption and allow the implementation of even more cost-effective devices and sensors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200918005116/en/ Cube Infrastructure Managers, the European infrastructu
Sensorion successfully raises approximately €31 (US$ 36.5) million in an oversubscribed private placement to US and European investors18.9.2020 09:00:00 EEST | Press release
Regulatory News: Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. This press release is not intended as an offer and is for informational purpose only Sensorion (Paris:ALSEN) (FR0012596468 – ALSEN – the “Company”) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders announces today the success of its previously announced capital increase. The Company has placed 18,236,000 new ordinary shares with a nominal value of €0.10 each (the “New Shares”), for total gross proceeds of approximately € 31 million by means of an accelerated bookbuild offering to the benefit of categories of persons (the “Reserved Offering”). The issue price of the New Shares is €1.70 per share, representing a 3.5% discount to the weighted average share price on the day preceding the date on which the issuance price
ESMO 2020: Phase II CLARINET FORTE Results Show Increasing Dose Frequencies of Somatuline® Autogel® (lanreotide) Allows Patients with NETs to Delay Treatment Escalation by up to 8.3 Months18.9.2020 08:00:00 EEST | Press release
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced the release of first efficacy and safety data from the CLARINET FORTE study, with the abstract to be presented as a mini-oral presentation at the 2020 European Society for Medical Oncology (ESMO) Congress, taking place virtually from 19-21 September 2020. The prospective single-arm, open-label, exploratory, international Phase II study investigated the efficacy and safety of increasing the dose frequency of Somatuline® Autogel ® (lanreotide) in patients with pancreatic or midgut NETs with centrally-assessed progression within the last two years while on a standard lanreotide regimen for ≥24 weeks. An extension of progression-free survival (PFS) rates and encouraging disease-control rates (DCR) were recorded in both tumor types, with no new safety signals. “These results support a clinically meaningful benefit to a population of patients with high unmet medical need by potentially delaying escalation to more toxic treatm
Vifor Pharma Group Announces Successful Sale of OM Pharma18.9.2020 08:00:00 EEST | Press release
Regulatory News: Vifor Pharma has today announced the successful sale of 100% of the share capital of OM Pharma, a Vifor Pharma Group company to Optimus Holding Ltd. The terms of the deal include: A purchase consideration of MCHF 435 for 100% of the share capital An earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity to be determined before the end of 2027 upon a trade sale, IPO or EBITDA multiple This earn out together with the purchase consideration could result in a total transaction value exceeding MCHF 500. The deal is expected to close within 30 days. OM Pharma is a Geneva-based company mainly active in the field of microbial derived immunotherapeutics and has developed strongly outside the core strategy of Vifor Pharma over the past few years. Optimus Holding Ltd. is a Swiss Group, founded by Etienne Jornod together with long-standing Swiss entrepreneurs and Abdi Ibrahim (28.5%), a Turkey-based pharmaceutical company operating in 12 countries a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom